ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Period-Dependent Survival Benefit of Percutaneous Microwave Ablation for Hepatocellular Carcinoma: A 12-Year Real-World, Multicentric Experience

Yu, Jie; Cheng, Zhi-Gang; Han, Zhi-Yu; Liu, Fang-Yi; Zheng, Rong-Qin; Cheng, Wen; Wei, Qiang; Yu, Song-Yuan; Li, Qin-ying; He, Guang-zhi; Luo, Yan-chun; Yu, Xiao-Ling; Liang, Ping*哈尔滨医科大学; 中山大学; 中国科学院研究生院; 5
Liver Cancer2022-7DOI: 10.1159/000522134
9被引15阅读
引用收藏
分享

摘要

Introduction: Although microwave ablation (MWA) is a promising technique for hepatocellular carcinoma (HCC) treatment, its 10-year efficacy is unknown. Objective: The objective of the study was to assess whether the advances in MWA for HCC translated into a real-world survival benefit. Methods: This retrospective study included 2,354 patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 to B from 5 hospitals, with at least 2 years of follow-up for all the patients. Recurrence and survival were analyzed using the Kaplan-Meier method with time-period stratification. Results: A total of 5,326 HCCs (mean diameter, 2.9 cm +/- 1.2) underwent 4,051 sessions of MWA with a median follow-up of 61.3 (0.6-169.5 range) months during 3 periods (2007-2010, 2011-2014, and 2015-2018). Technical success was achieved in 5,194 (97.5%) tumors with significant improvement over time, especially for >3.0-cm HCC (p < 0.001). Local tumor progression (LTP) showed no period-dependent advance, with >3.0-cm HCC and perivascular location being the risk factors for LTP. The median intrahepatic metastasis time was 27.6 (95% confidence interval [Cl]: 25.2-28.8) months, with 5- and 10-year occurrence rates of 68.8% and 79.4%, respectively. The 5- and 10-year overall survivals were 63.9% and 41.1%, respectively, and BCLC stage 0, A, and all B patients showed an observable survival improvement over time (p < 0.001). The median disease-free survival time increased from 19.4 (95% CI: 16.5-22.6) months in 2007-2010 to 28.1 (95% CI: 25.9-32.3) months in 2015-2018. The improved survival for early recurrent (s2 years) patients was period-dependent, as verified by Cox regression analyses. The major complications rate per procedure was 3.0% (122/4,051). Conclusions: These real-world data show that MWA provided an upward trend in survival for HCC patients with BCLC stage 0-B over a 12-year follow-up period. An encouraging clear survival benefit in early recurrent patients was also observed.

学科与关键词

关键词
Hepatocellular carcinomaMicrowave ablationPeriod-dependent survival benefitReal-world data
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Liver Cancer
发表日期
2022-07
卷期
第 11 卷, 第 4 期
页码
341-353
DOI
10.1159/000522134
期刊等级
1区
成果收录
SCIE

作者

  • Y

    Yu, Jie (第一作者)

    5 · chinese peoples liberat army gen hosp

  • C

    Cheng, Zhi-Gang

    5 · chinese peoples liberat army gen hosp

查看全部 13 位作者收起作者
  • H

    Han, Zhi-Yu

    5 · chinese peoples liberat army gen hosp

  • L

    Liu, Fang-Yi

    5 · chinese peoples liberat army gen hosp

  • Z

    Zheng, Rong-Qin

    sun yat sen univ

  • C

    Cheng, Wen

    harbin med univ

  • W

    Wei, Qiang

  • Y

    Yu, Song-Yuan

    wuhan univ sci & technol

  • L

    Li, Qin-ying

  • H

    He, Guang-zhi

    univ chinese acad sci

  • L

    Luo, Yan-chun

    5 · chinese peoples liberat army gen hosp

  • Y

    Yu, Xiao-Ling

    5 · chinese peoples liberat army gen hosp

  • L

    Liang, Ping (通讯)

    5 · chinese peoples liberat army gen hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417